TABLE 1.
Characteristic | Entire sample | Males (n = 144) | Females (n = 115) | |||||||
---|---|---|---|---|---|---|---|---|---|---|
(N = 259) | Expressed interest (n = 73) | Did not express interest (N = 71) | Expressed interest (N = 53) | Did not express interest (N = 62) | ||||||
Age at first fertility discussion during survivorship (years) | ||||||||||
Mean (SD) | 19.2 | (1.2) | 18.9 | (0.9) | 19.2 | (1.3) | 19.3 | (1.5) | 19.2 | (1.3) |
Median (range) | 18.7 | (18.0, 25.3) | 18.6 | (18.0, 21.8) | 18.7 | (18.0, 24.0) | 18.8 | (18.0, 25.3) | 18.8 | (18.1, 23.7) |
Age at diagnosis (years) | ||||||||||
Mean (SD) | 9.6 | (5.7) | 9.9 | (5.5) | 9.1 | (5.5) | 10.2 | (5.7) | 9.1 | (6.1) |
Median (range) | 10.3 | (0.1, 21.9) | 12.2 | (0.1, 18.8) | 8.4 | (0.3, 19.6) | 12.2 | (0.3, 21.0) | 8.0 | (0.4, 21.9) |
Time from cancer treatment completion (years) | ||||||||||
Mean (SD) | 8.0 | (5.2) | 7.3 | (5.1) | 8.4 | (5.0) | 7.8 | (5.7) | 8.6 | (5.1) |
Median (range) | 6.7 | (1.0, 21.5) | 5.6 | (1.5, 19.6) | 8.0 | (1.1, 21.5) | 5.4 | (1.3, 20.6) | 8.0 | (1.1, 18.1) |
N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | |
Race/ethnicity | ||||||||||
Non‐hispanic white | 150 | (57.9) | 42 | (51.2) | 40 | (48.8) | 31 | (45.6) | 37 | (54.4) |
Black | 67 | (25.9) | 18 | (45.0) | 22 | (55.0) | 15 | (55.5) | 12 | (44.4) |
Hispanic | 23 | (8.9) | 6 | (54.5) | 5 | (45.5) | 5 | (41.7) | 7 | (58.3) |
Asian | 8 | (3.1) | 1 | (33.3) | 2 | (66.7) | 2 | (60.0) | 3 | (40.0) |
Other | 11 | (4.2) | 6 | (75.0) | 2 | (25.0) | 0 | (0.0) | 3 | (100.0) |
Religion | ||||||||||
Christian | 142 | (54.8) | 36 | (50.1) | 37 | (49.3) | 33 | (47.8) | 36 | (52.2) |
Non‐christian or no preference | 64 | (24.7) | 17 | (45.9) | 20 | (54.1) | 12 | (44.4) | 15 | (55.6) |
Missing | 53 | (20.5) | 20 | (58.8) | 14 | (41.2) | 8 | (42.1) | 11 | (57.9) |
Geographical location by rural status | ||||||||||
Non‐rural | 229 | (88.4) | 68 | (52.3) | 62 | (47.7) | 47 | (47.5) | 52 | 52.5) |
Rural | 30 | (11.6) | 5 | (35.7) | 9 | (64.3) | 6 | (37.5) | 10 | (62.5) |
Insurance type | ||||||||||
Commercial/private | 180 | (69.5) | 50 | (51.0) | 48 | (49.0) | 43 | (52.4) | 39 | (47.6) |
Medicaid/self‐pay | 79 | (30.5) | 23 | (50.0) | 23 | (50.0) | 10 | (30.3) | 23 | (69.7) |
Cancer diagnosis category | ||||||||||
Leukemia | 95 | (36.7) | 23 | (40.4) | 34 | (59.6) | 13 | (34.2) | 25 | (65.8) |
Lymphoma | 67 | (25.9) | 23 | (63.9) | 13 | (36.1) | 15 | (48.4) | 16 | (51.6) |
Solid tumor | 97 | (37.5) | 27 | (52.9) | 24 | (47.1) | 25 | (54.3) | 21 | (45.6) |
Fertility preservation consult and/or procedure before treatment | ||||||||||
Yes | 30 | (11.6) | 16 | (66.7) | 8 | (33.3) | 1 | (16.7) | 5 | (83.3) |
No | 229 | (88.4) | 57 | (47.5) | 63 | (52.5) | 52 | (47.8) | 57 | (52.3) |
Hormonal laboratory evaluation a | ||||||||||
Within normal limits | 199 | (78.0) | 55 | (47.0) | 62 | (53.0) | 34 | (41.5) | 48 | (58.5) |
Outside normal limits | 56 | (22.0) | 17 | (65.4) | 9 | (34.6) | 16 | (53.3) | 14 | (46.7) |
Infertility risk | ||||||||||
Low | 147 | (56.8) | 28 | (38.9) | 44 | (61.1) | 31 | (41.3) | 44 | (58.7) |
Moderate | 41 | (15.8) | 15 | (60.0) | 10 | (40.0) | 8 | (50.0) | 8 | (50.0) |
High | 71 | (27.4) | 30 | (63.8) | 17 | (36.2)* | 14 | (58.3) | 10 | (41.7) |
Number of fertility discussions during survivorship | ||||||||||
1 | 164 | (63.3) | 37 | (39.4) | 57 | (60.6) | 25 | (35.7) | 45 | (64.3) |
≥2 | 95 | (36.7) | 36 | (72.0) | 14 | (28.0)*** | 28 | (62.2) | 17 | (37.8)** |
Survivor expressed worry about future infertility b | ||||||||||
Yes | 165 | (63.7) | 52 | (63.4) | 30 | (36.6) | 46 | (55.4) | 37 | (44.6) |
No | 94 | (36.3) | 41 | (66.1) | 21 | (33.9)*** | 7 | (21.9) | 25 | (78.1)** |
Proportions are presented as row percentages. Differences in interest in fertility status assessment by sex were assessed using chi‐square or fisher's exact test for categorical data and t‐test or Mann–Whitney U for continuous data.
Abbreviation: SD, standard deviation.
Proportions were calculated by excluding missing values (n = 4). Hormonal laboratory values outside of normal limits for males included a follicle stimulating hormone (FSH) ≥12.0 and for females included either an FSH ≥40.0 and/or an anti‐Mullerian hormone level below the lower limit of the assay‐specific reference range.
Survivors were asked if they were worried about future infertility as part of the fertility discussion.
*p < 0.05; **p < 0.01; ***p < 0.001.